CNAG has contributed to describing the most comprehensive map of cancer genomes from 38 types of tumours

By February 17, 2020February 24th, 2020CRG

The Centre Nacional d’Anàlisi Genòmica (CNAG-CRG), part of the Centre for Genomic Regulation, a BIST centre, is part of an international team of scientists that published 23 studies in Nature journals this month, describing the most comprehensive map of cancer genomes from 38 types of tumours. The results are an important step for the development of personalized medicine.

Scientists have previously looked for genes linked to the proliferation of cancer in the 1% of the human genome that codes for proteins. Now, the ‘Pan-Cancer Analysis of Whole Genomes Project’ (PCAWG) consortium of scientists have sequenced the remaining 99% of the genome, developing new methods for researching the role of the ‘dark genome’ and finding new causes of cancer, new ways to prevent and diagnose it, as well as new treatments.

Catalonia has contributed to the project through sequencing 95 primary tumours of chronic lymphatic leukaemia in the Centre Nacional d’Anàlisi Genòmica (CNAG-CRG), which is part of the Centre for Genomic Regulation, a BIST centre. CNAG-CRG is under the direction of Prof. Ivo Gut who also leads the Biomedical Genomics Group there.

The main findings across all 23 studies are:

The cancer genome is finite and knowable, but enormously complicated. By combining sequencing of the whole cancer genome with a suite of analysis tools, we can characterize every genetic change found in a cancer, all the processes that have generated those mutations, and even the order of key events during a cancer’s life history.

– Researchers are close to cataloguing all of the biological pathways involved in cancer and to having a fuller picture of their actions within the genome. At least one causal mutation was found in virtually all of the cancers analyzed and the processes that generate mutations were found to be hugely diverse: from changes in single DNA letters to the reorganization of whole chromosomes. This will help diagnose cancer and identify new therapeutic targets for drugs.

– A new “carbon dating” method identifies mutations which occurred years, sometimes even decades, before the tumour appears. This theoretically opens a window of opportunity for early cancer detection.

– Tumour types can be identified accurately according to the patterns of genetic changes seen throughout the genome, offering clues as to what causes the disease. Smoking and sunbathing leave distinct patterns while hereditary disorders leave others. The consortium has catalogued these patterns, which can be compared with those found in the genome of a cancer patient to facilitate diagnosis where conventional clinical tests could not identify its type.

The ‘Pan-Cancer Analysis of Whole Genomes Project’ (PCAWG) is an international consortium consisting of 1,300 scientists from 70 research centres across 37 different countries, considered by some to be the “United Nations” of cancer genome sequencing. It is the world’s biggest cancer genome sequencing project to date. The 5,000 genomes from 2,658 donors (one sample from the cancer genome and another from the healthy base for each donor) generated more than 800 terabytes of information. The database will be a free resource for researchers, accelerating new discoveries such as new therapeutic targets for existing pharmaceuticals.

These findings are key for the development of personalized medicine, once sequencing the genome of a cancer becomes commonplace in a clinical setting,” says Ivo Gut, CNAG-CRG Director and chair of one of the working groups that make up the PCAWG. “In a not so distant future we will be able to precisely diagnose the type of tumour people have, predict its progression with more accuracy and choose the most effective treatment.

This huge international study was only possible due to the work and collaboration of more than a thousand researchers and clinicians across the world, and I would like to thank everyone involved,” said steering committee member Dr. Jan Korbel from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.

This work is helping to answer a long-standing medical difficulty, why two patients with what appear to be the same cancer can have very different outcomes to the same drug treatment. We show that the reasons for these different behaviours are written in the DNA. The genome of each patient’s cancer is unique, but there are a finite set of recurring patterns, so with large enough studies we can identify all these patterns to optimize diagnosis and treatment.” said Dr. Peter Campbell, member of the Pan-Cancer Project steering committee and Head of Cancer, Ageing and Somatic Mutation at the Wellcome Sanger Institute in the UK.

The project was founded at the Ontario Institute of Cancer Research in Canada and is now based at the University of Glasgow in Scotland. Amongst the 1,300 scientists who have contributed to the project we find researchers based at the CNAG-CRG, the Centre for Genomic Regulation, Pompeu Fabra University, the Institute of Evolutionary Biology, the University of Santiago de Compostela, the Institute for Research in Biomedicine and the Barcelona Supercomputing Centre.

More information can be found on the CNAG-CRG website.